Repligen Announces Strategic Partnership With Novasign To Further Advance The Digitalization Of Bioprocessing Technologies

Repligen Corporation, a life sciences company known for its bioprocessing technologies, has announced a strategic partnership with Novasign to advance the integration of machine learning and modeling into bioprocessing workflows. As part of this collaboration, Repligen will invest in Novasign to support the expansion and scaling of its operations.

The partnership will focus on incorporating Novasign’s machine learning-based modeling workflow into Repligen’s tangential flow filtration (TFF) systems. This integration is expected to accelerate Repligen’s digital transformation efforts by enhancing its suite of process analytical technology (PAT)-enabled systems and laying the foundation for more advanced AI modeling capabilities within its product platforms.

Ralf Kuriyel, Senior Vice President, Research and Development at Repligen, said in a statement, “We are excited to partner with Novasign, a leader in bioprocessing modeling technology. Our partnership underscores Repligen’s dedication to advancing toward smart digital manufacturing. By integrating our automated manufacturing systems with smart sensors and Novasign’s digital twins capability, we will provide technology to accelerate process development and ensure a more efficient and reliable scale-up for our customers.”

Mark Duerkop, Chief Executive Officer at Novasign, mentioned, “The fusion of intelligent modeling workflows, PAT and smart devices will allow the industry to drastically reduce development costs while unlocking deeper process understanding. We’ve already laid the groundwork for this collaboration through earlier joint efforts with Repligen on its PAT technologies, and we’re proud to now take it to the next level with joint development. This strategic partnership represents a strong endorsement of Novasign’s innovation and long-term role in advancing bioprocess digitalization.”

By embedding Novasign’s digital tools into its systems, Repligen aims to streamline bioprocess development, enable real-time predictive process control, and reduce both development time and cost. The deployment of digital twins virtual replicas of physical processes will allow users to simulate, optimize, and control bioprocesses more efficiently and accurately.

Novasign brings a strong background in bioprocessing, software development, and modeling. Its AI-powered platform supports various stages of biomanufacturing, including cultivation, harvesting, filtration, and chromatography. The models are adaptable across different products, modalities, and production scales, providing actionable insights and enabling smarter, faster decision-making in process development while reducing overall risk.